NCT03951571已完成2 期
Efficacy and Safety of Anlotinib Hydrochloride (AL3818) in Postoperative Adjuvant Therapy for High-grade Soft Tissue Sarcoma -- A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trail
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 5
- 主要终点
- 1-year and 2-year DFR
研究概览
简要总结
To evaluate the efficacy and safety of Anlotinib Hydrochloride Capsule combined with Best Supportive Therapy in the adjuvant treatment of patients with high-grade soft tissue sarcoma after operation, as compared with placebo combined with Best Supportive Therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.High-grade soft tissue sarcoma patients without standard adjuvant chemotherapy after surgery. Mainly includes: liposarcoma(except for Myxoid/round cell liposarcoma), leiomyosarcoma, malignant peripheral nerve sheath tumor, fibrosarcoma, clear cell sarcoma, alveolar soft part sarcoma, angiosarcoma, epithelioid sarcoma, malignant solitary fibrous tumor and so on. Except for rhabdomyosarcoma, gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, Ewing sarcoma/primary neuroectodermal tumors, inflammatory myofibroblastoma, malignant mesothelioma.
- •2.The postoperative microscopic margin was negative and the pathological diagnosis was high-grade soft tissue sarcoma. The diagnosis was completed by pathologists, and the pathological specimens were confirmed by the research center.
- •3.The age is ≥18 years old, the ECOG score is ≤2, and the estimated survival time is more than 3 months.
- •4.Examinations meet the following criteria:
- •Blood routine examination: HB ≥ 100g/L(no blood transfusion within 14 days); ANC ≥ 1.5×10^9 /L; PLT ≥ 80×10^9 /L
- •Other examinations: Cr ≤ upper limit of normal value (ULN); BIL ≤ ULN; ALTAST ≤ 1.5 × ULN (for patients with liver metastasis ≤ 5 × ULN); fasting triglyceride ≤3.0mmol/L; fasting cholesterol ≤7.75mmol/L;
- •Doppler ultrasound assessment: LVEF ≥ 50%.
- •Females should agree to use contraceptives (such as intrauterine devices (IUD), birth control pills or condoms) during the study period and 6 months after the end of study and the serum or urine pregnancy test was negative within 7 days prior to study enrollment and must be non-lactating; Males should agree to use contraception during the study period and within six months after the end of the study period.
- •6.Patients should participate in the study involuntarily, sign the informed consent, and have good compliant and agree to be followed up.
排除标准
- •Patients who have received targeted therapy of vascular endothelial growth inhibitors, such as sunitinib, sorafenib, bevacizumab, imatinib, famitinib and apatinib, etc.
- •Patients who have malignant tumors previously or concomitantly, except for cured skin basal cell carcinoma and cervical carcinoma in situ;
- •Those who participated in other drug clinical trials within 4 weeks;
- •Those who received chemotherapy within 4 weeks.
- •Those who received anticancer therapy previously and have toxic reactions of NCI-CTC AE grade > grade 1 now;
- •Patients who have multiple factors affecting oral medication (such as inability to swallow, Post-gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.);
- •Patients who have brain metastases, spinal cord compression, cancerous meningitis, or screening CT or MRI findings of brain or pia mater disease.
- •Patients have any serious or uncontrolled disease, such as:
- •Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmia; patients with unsatisfactory blood pressure control (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg);
- •Active or uncontrolled severe infections;
- •Liver diseases such as cirrhosis, decompensated liver disease and chronic active hepatitis;
- •Poor control of diabetes mellitus (FBG > 10mmol/L);
- •Urinary routine examination showed that urinary protein (++) and confirmed by the 24-hour urinary protein quantification(>1.0 g);
- •Long-term unhealed wound or fracture
- •Patients with bleeding tendency (e.g. active gastrointestinal ulcer) or treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues.
- •Arterial or venous thrombosis occurred before the first dose, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism.
- •Those who have a history of psychotropic drug abuse and are unable to get rid of or have mental disorders.
- •Those who have a history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disorders, or organ transplantation.
- •According to the investigator's assessment, there are serious concomitant diseases that endanger the safety of the patient or affect the patient's completion of the study.
研究组 & 干预措施
Anlotinib Gruop
Experimental
干预措施: Anlotinib Hydrochloride (Drug)
Placebo Group
Placebo Comparator
干预措施: Placebo Oral Tablet (Drug)
结局指标
主要结局
1-year and 2-year DFR
时间窗: 2 years
1-year and 2-year disease-free survival rates
DFS
时间窗: 2 years
Disease Free Survival
次要结局
- OS(2 years)
- LRFS(2 years)
- DMFS(2 years)
研究者
Chunmeng Wang
Director, Head of Musculoskeletal Oncology, Principal Investigator, Clinical Professor
Fudan University
研究点 (5)
Loading locations...
相似试验
已完成
2 期
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerLung CancerNCT04671303Cancer Institute and Hospital, Chinese Academy of Medical Sciences36
Unknown
2 期
Anlotinib or Penpulimab in Combination With RAI for DTCThyroid CancerNCT04952493Peking Union Medical College Hospital42
尚未招募
3 期
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerEndometrial CancerNCT06475599Chia Tai Tianqing Pharmaceutical Group Co., Ltd.420
撤回
2 期
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal CancerNeoadjuvant TreatmentRectal CancerAnlotinibNCT04620473Shanghai Minimally Invasive Surgery Center
Unknown
不适用
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKINSCLCNCT04007835Guangdong Association of Clinical Trials120